Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 17/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL31033178 | 0.90 | KLKB1 (0.48) | KLKB1BTK | |
| SCHEMBL31033242 | 0.88 | KLKB1 (0.45) | KLKB1BTK | |
| SCHEMBL21713031 | 0.88 | KLKB1 (0.45) | KLKB1BTK | |
| SCHEMBL22166243 | 0.86 | KLKB1 (0.59) | KLKB1L3MBTL1BTK | |
| SCHEMBL21736635 | 0.84 | KLKB1 (0.45) | KLKB1ALKBH1 | |
| SCHEMBL20541454 | 0.84 | KLKB1 (0.62) | KLKB1 | |
| SCHEMBL21736751 | 0.84 | KLKB1 (0.62) | KLKB1 | |
| SCHEMBL23469646 | 0.83 | KLKB1 (0.47) | KLKB1BTK | |
| SCHEMBL20540796 | 0.83 | KLKB1 (0.47) | KLKB1BTK | |
| SCHEMBL21736642 | 0.82 | KLKB1 (0.44) | KLKB1L3MBTL1ALKBH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| WO-2020035540-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-02-20 | — | — | WO | disclosed |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-02-20 | — | — | US | disclosed |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885L3MBTL1 4291/4885BTK 1297/4885 |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885L3MBTL1 4291/4885BTK 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.